PL414021A1 - Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours - Google Patents
Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumoursInfo
- Publication number
- PL414021A1 PL414021A1 PL414021A PL41402115A PL414021A1 PL 414021 A1 PL414021 A1 PL 414021A1 PL 414021 A PL414021 A PL 414021A PL 41402115 A PL41402115 A PL 41402115A PL 414021 A1 PL414021 A1 PL 414021A1
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- pharmaceutical formulation
- dexorubicin
- tumours
- formulation containing
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem zgłoszenia jest formulacja farmaceutyczna o właściwościach przeciwnowotworowych zawierająca doksorubicynę i co najmniej jeden izotiocyjanian jako substancję wzmacniającą działanie doksorubicyny do zastosowania w leczeniu nowotworu, przy czym doksorubicyna i co najmniej jeden izotiocyjanian umieszczone są w nośniku lipidowym.The subject of the application is a pharmaceutical formulation with anti-cancer properties comprising doxorubicin and at least one isothiocyanate as a substance enhancing the action of doxorubicin for use in the treatment of cancer, wherein doxorubicin and at least one isothiocyanate are placed in a lipid carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL414021A PL229503B1 (en) | 2015-09-21 | 2015-09-21 | Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL414021A PL229503B1 (en) | 2015-09-21 | 2015-09-21 | Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours |
Publications (2)
Publication Number | Publication Date |
---|---|
PL414021A1 true PL414021A1 (en) | 2017-03-27 |
PL229503B1 PL229503B1 (en) | 2018-07-31 |
Family
ID=58360332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL414021A PL229503B1 (en) | 2015-09-21 | 2015-09-21 | Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL229503B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL238526B1 (en) * | 2018-09-04 | 2021-08-30 | Narodowy Inst Lekow | Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity |
PL241189B1 (en) * | 2018-09-27 | 2022-08-22 | Narodowy Inst Lekow | Pharmaceutical formulation containing selenitetrigliceride and cytostatic for use in cancer treatment |
-
2015
- 2015-09-21 PL PL414021A patent/PL229503B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL229503B1 (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001609A1 (en) | Pharmaceutical compositions comprising azd9291. | |
CL2016000807A1 (en) | Amino heteroaryl benzamides as kinase inhibitors. | |
MY197324A (en) | Adenovirus armed with bispecific t cell activator | |
ECSP16075472A (en) | CONJUGATES OF ANTI-DROSOPHILA SIMILAR ANTIBODIES TO DELTA 3 (ANTI-DLL3) AND DRUGS FOR USE IN THE TREATMENT OF MELANOMA | |
SV2017005461A (en) | BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO | |
CO2017001994A2 (en) | Active compounds towards bromodomains | |
CL2015001985A1 (en) | Thiazolcarboxamides and pyridinecarboxamide compounds, pim kinase inhibitors. | |
SV2017005355A (en) | CARRIER-ANTIBODY COMPOSITIONS AND METHODS TO PERFORM AND USE THEM | |
MX2017013613A (en) | Cancer neoepitopes. | |
CL2014001865A1 (en) | Phosphate derived compounds; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer. | |
ECSP15026557A (en) | COMPOUNDS AND THEIR METHODS OF USE | |
CL2015002194A1 (en) | Erk inhibitors and their uses | |
CL2016002516A1 (en) | "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct | |
BR112015011756A2 (en) | glutamase inhibitors and methods of use | |
CL2018000222A1 (en) | New combination for use in cancer treatment | |
CL2014001829A1 (en) | Compounds derived from indolizine; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer. | |
DOP2015000108A (en) | PIRROLOPIRIMIDINE COMPOUNDS AS QUINASE INHIBITORS | |
BR112015019064A2 (en) | melanoma treatment methods | |
CL2014003465A1 (en) | Antibody that binds to the dimeric human epidermal growth factor receptor (hegfr); pharmaceutical composition comprising it; and use to treat cancer. | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
CL2013000018A1 (en) | Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others. | |
BR112015016681A8 (en) | use of nanoparticles comprising paclitaxel and an albumin, kit, drug, composition and unit dosage form for the treatment of pancreatic cancer | |
MX2015009106A (en) | Solid solution compositions and use in severe pain. | |
CL2018000963A1 (en) | Cosmetic that has probiotic bacteria | |
CL2015003343A1 (en) | Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images. |